RobecoSAM Includes Sanofi in "Silver Class"
of its 2014 Sustainability Yearbook
Paris, France - January 30, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that RobecoSAM, which measures the performance of companies in terms of corporate social responsibility (CSR), has included Sanofi for the seventh consecutive year in the 2014 Sustainability Yearbook published this month. As one of the top-scoring companies in the pharmaceutical industry, Sanofi has also received the Silver Class distinction for its excellent sustainability performance, a significant improvement over last year's rankings.
"Sanofi is proud of this recognition which underscores that sustainability is an integral part of how we conduct our daily activities around the world," said Gilles Lhernould, Senior Vice President, CSR, Sanofi. "As a global healthcare leader present in more than 100 countries we not only have the ability, but also a responsibility to make a difference."
Sanofi reached a total score of 83 (+6 compared to 2012) and improved on 14 areas. The Group has also been evaluated as being among the Best in Class for the following areas: Marketing Practices, Talent Attraction & Retention, Corporate Citizenship & Philanthropy as well as Strategy to Improve Access to Drugs or Products.This ranking is based on the annual Corporate Sustainability Assessment (CSA) performed by RobecoSAM which determines companies' inclusion in the Dow Jones Sustainability Indexes (DJSI). As announced in September 2013, Sanofi is included in the DJSI World.
More than 3,000 of the world's largest companies, including 800 companies based in the emerging markets, are invited to participate in RobecoSAM's Corporate Sustainability Assessment (CSA) every year. Only the top 15% of the companies from each industry is included in The Sustainability Yearbook. Sanofi is among the 460 companies listed in this Yearbook, and among the 65 companies which have received the Silver Class distinction.
The criteria assessed for the ranking include a series of specific economic, environmental and social metrics. For further details, see the interactive RobecoSAM 2014 Sustainability Yearbook http://yearbook.robecosam.com/
To learn more about Sanofi's CSR priorities please visit http://en.sanofi.com/csr/csr.aspx
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
| Contacts: |
Tel: +33 (0)1 53 77 46 46
| Investor Relations |
Tel: +33 (0)1 53 77 45 45